B-cell dysplasia has been reported for up to 5 years after anti-CD19 CAR-T-cell treatment for B-ALL.72 Infections are very common after CAR-T-cell therapy, mostly occurring within 1 to 2 years, and the incidence of infection is approximately 55%. Here, CD19 is linked to infection.